Economic impact of a clinical pharmacist in the orthopaedic sector: a review of the literature.

This review of the literature aimed to evaluate the economic impact of a clinical pharmacist in the orthopaedic sector. The review followed the PRISMA recommendations. A bibliographic search was conducted on 23 June 2023 using PubMed, Cochrane Library and Web of Science. All articles in French or English with economic data on clinical pharmacy activities in orthopaedics were included. Articles not mentioning the term 'orthopaedics' and those published prior to 1990 were excluded. Data from the studies were compiled in an Excel table. A bias analysis using the ROBINS-I Cochrane tool was performed. The methodology of the studies was compared and weighted using the CHEERS and STROBE checklists. Among 529 articles initially identified, 10 were included in the review. The cost-benefit ratio of a clinical pharmacist in orthopaedics ranged from 0.47:1 to 28:1. The maximum savings reached US$73 410 /year in the American study and €1 42 356 /year in the French study. For three studies, the cost of a clinical pharmacist was not evaluated. Eight studies showed a positive economic impact. The Dutch study showed a balance and the Danish study showed a negative economic impact of €3442/month. This literature review has shown an economic benefit of a clinical pharmacist in the orthopaedic sector despite several biases and methodological limitations. The two studies that did not confirm this benefit only evaluated a limited number of expected benefits. Nevertheless, the economic impact of the clinical pharmacist in the orthopaedic sector seems positive and undervalued.

Informations de copyright

© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JD, AS, EB do not have any conflicts of interest. CC received non-monetary benefits (hospitality) from Biogen France SA. FD has a consulting role with Amplitude, Serf, Stryker, Zimmer, Heraeus, Leo Pharma unrelated to this work. RV has an expert role with Biomarin, LFB, Lilly, Novartis, Novonordisk, Roche, Sanofi and Sobi. He also received support (conferences) from Mylan, Sobi and Takeda. JC received non-monetary benefits from Smith & Nephew, Zimmer Biomet, Riv’Ortho, Lépine, SERF and Sanofi-Aventis (hospitality). No competing interest related to the study.